Navigation Links
Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184
Date:1/9/2012

virus (LLOQ < 25 IU/ml) at 28 days. Currently 87% of patients in the 100 mg arm and 94% in the 50 mg arm had undetectable virus at a median of 8 weeks of treatment. There have been no virologic breakthroughs observed in the study to date.

"These interim results are encouraging as they confirm the antiviral activity and safety of IDX184 in combination with pegylated interferon and ribavirin," Eric Lawitz, M.D., of Alamo Medical Research, Camden Medical Center, stated. "Nucleotide drugs such as IDX184 are becoming an important component in the rapidly evolving treatment regimens for HCV. Eventually, the goal for treatment will be to reduce or eliminate reliance on interferon and to shift to all oral combinations of direct-acting antiviral agents that can reduce potential side effects and decrease the amount of time on therapy."

Ron Renaud, President and Chief Executive Officer of Idenix, commented, "We are very pleased with the interim results for IDX184 and with the progress we made in 2011 across our programs. In 2012, we will build on this progress and believe we are well positioned to play a major role in treating HCV patients for the foreseeable future."

ABOUT IDX184
IDX184 is an unpartnered, novel, liver-targeted nucleotide prodrug of 2'-methyl guanosine, which includes Idenix's proprietary liver-targeting technology.  This technology enables the delivery of nucleoside monophosphate to the liver, leading to the formation of high levels of nucleoside triphosphate, potentially maximizing drug efficacy and limiting systemic side effects with low, once-daily dosing. IDX184 is currently being developed under a partial clinical hold.

ABOUT IDENIX
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases.  Idenix's current focus is on the treatment of patients with hepat
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Idenix Reports Advancement of HCV Development Pipeline
2. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Idenix Pharmaceuticals to Present at Three Upcoming Investor Conferences
4. Idenix to Host Conference Call Discussing Second Quarter and Six Month 2011 Financial Results
5. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
6. Idenix Pharmaceuticals to Hold an Investor/Analyst Day Event on October 30, 2010
7. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
10. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 iLab Solutions, the ... as the new Director of Product Strategy. In this role, ... as iLab sub-teams to guide in the development of iLab ... provides the maximum possible benefit to the scientific community by ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental ... about dual arch impressions on its dental blog. ... blog entry serves up a list of tips to help ... by Dr. David Little as he crafts a porcelain crown ...
(Date:1/14/2014)... 14, 2014 BioMedomics, Inc. , a ... diagnostic platforms and novel disease specific POC tests, announced today ... netting a total of $690,000. The investment is from private ... company. This group of private investors has significant successful experience ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2BioMedomics, Inc. Closes $690K Round of Financing 2
... Madison has long been a home of innovation for entrepreneurs, as ... for them to place their roots. With over 120 technology companies ... growth has led Forbes Magazine to place it first ... ,Every company in Madison has a major project in mind when ...
... Small Times editor discusses nanotech trends at conference , ... week at the University of Wisconsin-Madison, a man with a ... small stuff said Wisconsin is bursting with venture capital ... nanotechnology magazine Small Times , has good reason to ...
... the Wisconsin Technology Network sat down with Tom Still, ... to discuss the basic tenants and initiatives Still and ... grow. This is the first portion of a two-part ... the Wisconsin Technology Council is working to overcome them. ...
Cached Biology Technology:The NeuronFarm works to increase reading comprehension 2The NeuronFarm works to increase reading comprehension 3The NeuronFarm works to increase reading comprehension 4Wisconsin places high in nanotech venture capital, average in innovation 2WTN exclusive interview with Tom Still, Wisconsin Technology Council 2WTN exclusive interview with Tom Still, Wisconsin Technology Council 3WTN exclusive interview with Tom Still, Wisconsin Technology Council 4WTN exclusive interview with Tom Still, Wisconsin Technology Council 5
(Date:4/17/2014)... Yokahama IPCC meeting painted a stark warning on the ... has a greenhouse effect 32 times that of carbon ... that humic substances act as fully regenerable electron acceptors ... held in wetlands instead of being released to the ... is disrupted it may enter into a vicious cycle ...
(Date:4/17/2014)... chock full of wild animals and plant life, but ... are churning away in the soil, decomposing organic matter ... vital role these fungi play in ecological systems, their ... of scientists has generated a genetic map of more ... work was published this week in the Proceedings ...
(Date:4/16/2014)... Nicaragua,s legal, artisanal green sea turtle fishery has uncovered ... turtles in what may have become an unsustainable take, ... and University of Florida. , During the research period, ... were killed between 1991 and 2011, with catch rates ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3
... for sleeping sickness, carried out by the international humanitarian ... research arm, Epicentre, have now been published in the ... sickness affects many tens of thousands of people each ... for which there are few treatment options. The most commonly ...
... are releasing methane, a greenhouse gas, at rates that appear ... acting as a positive feedback to climate warming, said Katey ... , Walter's project is the first time this type of ... estimates were missing a very large and important component of ...
... As part of the international Census of Marine Life ... on an expedition to explore coral reef biodiversity in ... Northwestern Hawaiian Islands Marine National Monument. Led by ... Fisheries Science Center, with funding from NOAA's Coral Reef ...
Cached Biology News:Siberian lakes burp 'time-bomb' greenhouse gas 2First Biodiversity Census of coral reef ecosystems in the NW Hawaiian Islands 2First Biodiversity Census of coral reef ecosystems in the NW Hawaiian Islands 3
Rabbit monoclonal [E227] to ZAP70 (phospho Y319) ( Abpromise for all tested applications). Antigen: Synthetic phospho peptide corresponding to residues surrounding Tyr319 of human ZAP70 Entre...
Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Biology Products: